Identifiers
C-C motif chemokine ligand 5
HUGO:CCL5 hgnc_id:HGNC:10632 HGNC:10632 ENTREZ:6352 UNIPROT:P13501
HUGO:CCL5
Maps_Modules
HMC:TUMOR_PROMOTING_INFLAMMATION
HMC:ACTIVATING_INVASION_AND_METASTASIS
Cancer Associated Fibroblasts / CYTOKINES_CHEMOKINES_PRODUCTION
Cancer Associated Fibroblasts / TREG_MODULATORS
HMC:AVOIDING_IMMUNE_DESTRUCTION
Innate Immunity / RECRUITMENT_OF_IMMUNE_CELLS
References
PMID:23171795
Downregulation of miR-31 and miR-214 and upregulation of miR-155 was confirmed in all CAF and induced CAF samples;
CCL5 is a Target of miR-214 . The CCL5 secreted by CAFs is a key tumor-promoting factor.
PMID:21326202
CAFs may be the stromal source of the T cell attracting chemokine CCL5/RANTES, recruiting Treg cells into primary mammary tumors, which in turn stimulate metastatic progression
CCL5 neutralization also inhibited recruitment of tumor-associated CD25+ cells in vivo
Expression of CCR1, one of the cognate CCL5 receptors22, was strongly elevated in tumor CD4+ T cells relative to splenic CD4+ T cells of tumor-bearing or na??ve mice. Notably, CD4+CD25+ tumor T cells expressed more Ccr1 mRNA than CD4+CD25??? tumor T cells
PMID:23567181
CCL5/RANTES and CCL2 secreted by CAFs isolated from human melanoma, breast and colon cancers mediated recruitment of Th17 cells from peripheral blood
NEUTROPHIL
DENDRITIC_CELL
NATURAL_KILLER
CASCADE:CCR5
CASCADE:TGFB
PMID:19732719??
Inhibition of TGF-?? signaling downregulates Arginase1, CCL5 and CCL2 expression and upregulates TNF, ICAM1,CCL3 expression (mRNA) in tumor neutrophiles (TAN)
PMID:11698286
IFNA induces surface expression of CCR5 in Dcs. This higher expression of CCR5 was associated with a stronger chemotactic response of IFN-DCs to the ??-chemokines CCL5(RANTES), CCL3(MIP-1??), and, especially, CCL4( MIP-1??).
PMID:11790543, PMID:15356122
CCR5 as a critical NK-cell homing receptor,
CCL5 expression at the tumor site determined the effectiveness of the antitumor response, which was associated with infiltration of increased numbers of NK, CD4, and CD8 cells at the tumor site.